{
  "Table Title": "Table 1 Baseline characteristics by treatment group",
  "Source": "Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial",
  "Data": [
    {
      "Category": "Clinical",
      "Characteristic": "No. of participants",
      "Values": {
        "Placebo": "20",
        "Semaglutide": "20",
        "Empagliflozin": "20",
        "Combination": "20",
        "p value": "–"
      }
    },
    {
      "Category": "Clinical",
      "Characteristic": "Age, years",
      "Values": {
        "Placebo": "64.6 ± 6.1",
        "Semaglutide": "70.1 ± 6.8",
        "Empagliflozin": "69.6 ± 6.0",
        "Combination": "67.9 ± 6.2",
        "p value": "0.03"
      }
    },
    {
      "Category": "Clinical",
      "Characteristic": "Male sex",
      "Values": {
        "Placebo": "14 (70)",
        "Semaglutide": "17 (85)",
        "Empagliflozin": "13 (65)",
        "Combination": "17 (85)",
        "p value": "0.32"
      }
    },
    {
      "Category": "Clinical",
      "Characteristic": "BMI, kg/m2",
      "Values": {
        "Placebo": "33 ± 6",
        "Semaglutide": "32 ± 5",
        "Empagliflozin": "33 ± 6",
        "Combination": "31 ± 5",
        "p value": "0.38"
      }
    },
    {
      "Category": "Clinical",
      "Characteristic": "Duration of diabetes, years",
      "Values": {
        "Placebo": "8.0 (4.0–10.0)",
        "Semaglutide": "8.5 (3.5–16.0)",
        "Empagliflozin": "10.0 (5.0–18.5)",
        "Combination": "6.0 (2.3–12.0)",
        "p value": "0.46"
      }
    }
  ]
}
